

To whom it may concern

Date: September 30th, 2025

Company Name : StemCell Institute Inc.
Representative : President Takafumi Shimizu
(Code Number: 7096; Tokyo Stock Exchange Growth)
Company Name : iPS Portal, Inc.
Representative: President Masakazu Kobayashi

**Notice of Conclusion of Joint Research Agreement on
Umbilical Cord Blood-Derived Autologous iPS Cell Banking Service
StemCell Institute Inc. and iPS Portal, Inc.**

**Launch of “Study on the Development of Manufacturing and Storage Processes for Autologous iPS Cells
Derived from Umbilical Cord Blood and Their Clinical Applications”**

StemCell Institute Inc. (Minato-ku, Tokyo; President and CEO: Takafumi Shimizu; TSE Growth: 7096; hereinafter “StemCell Institute”) and iPS Portal, Inc. (Kyoto City, Kyoto Prefecture; President and CEO: Masakazu Kobayashi; hereinafter “iPS Portal”) have launched a joint research project aimed at realizing a service for manufacturing and storing iPS cells from stored autologous umbilical cord blood, with a view toward their future clinical use.

In this joint research, StemCell Institute will contribute its expertise in umbilical cord blood collection and long-term storage, as well as its efforts to promote the medical use of stored autologous cord blood. iPS Portal will contribute its proven track record in the manufacturing and clinical development of autologous cell-derived iPS cells. Together, the two companies aim to establish a process for the manufacturing, storage, and clinical application of iPS cells derived from autologous cord blood. By ensuring the reliable production of iPS cells from long-term stored cord blood and developing a system that enables pre-manufactured iPS cells to be stored, the two companies will combine their strengths to promote the development of new medical applications.

iPS cells can be induced from virtually any somatic cell and are an extremely promising cellular resource for regenerative medicine and the development of new therapies. In particular, autologous iPS cells—derived from the patient’s own cells—have extremely high immunological compatibility, thereby avoiding immune rejection responses that can arise with allogeneic transplants. In this respect, they have a decisive advantage over allogeneic iPS cells.

Moreover, producing iPS cells from umbilical cord blood offers unique benefits. Because cord blood is collected immediately after birth, it is biologically very young and is thought to carry fewer accumulated genome mutations* and epigenetic modifications** that accumulate with repeated cell division in adult-derived somatic cells. As a result, it is possible to manufacture iPS cells with higher genomic stability, greater uniformity, and improved safety.

In the future, the establishment of therapies using autologous cord blood-derived iPS cells is expected to create a framework in which users of StemCell Institute’s cord and cord blood storage services can access these new treatments through iPS Portal’s iPS cell manufacturing service and benefit from them.

*Genome mutations: Refers to changes that occur in the DNA sequence during processes such as repeated cell

division. These include errors, deletions, or substitutions in genetic information, which can sometimes affect the characteristics of the cell.

****Epigenetic modifications:** Refers to phenomena in which the activity of genes changes due to partial chemical modifications of the DNA, even though the DNA sequence itself remains unchanged. These modifications are known to accumulate with aging and environmental factors.

※This matter is expected to have only a minor impact on the business performance of StemCell Institute.

■ iPS Portal, Inc.

Our company contributes to the advancement of life sciences by promoting research and commercialization across the entire industry through “Cell-Tech,” which integrates cutting-edge technologies such as iPS cells, other stem cell technologies, and genome editing. Our efforts are not limited to drug discovery and regenerative medicine but also extend to lifestyle disease prevention, health, and beauty fields.

Established: July 31, 2014

Capital, etc.: 831 million yen (Capital: 99 million yen, Capital reserve: 732 million yen)

President & CEO: Masakazu Kobayashi

Head Office: 103-5 Tanaka Monzen-cho, Sakyo-ku, Kyoto City, Louis Pasteur Center for Medical Research Building

TEL / Website: 075-707-1057 / <https://ipsportal.com/>

■ StemCell Institute Inc.

With the corporate slogan “*Providing new medical care solutions for every new life*”, our company operates cell banking businesses for perinatal tissue-derived cells such as the “umbilical cord” and “cord blood,” leveraging a strong network with obstetrics and gynecology facilities. Our aim is to develop new therapies and products using these cells for regenerative and cell therapy purposes. Based on this business foundation, we strive for sustainable growth and social contribution by developing businesses and making investments in related fields such as regenerative medicine and femtech.

Established: August 5, 1999 (Listed on TSE Growth: 7096)

Capital: 704.8 million yen

President & CEO: Takafumi Shimizu

Head Office: 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001

TEL / Website: 03-6811-3230 / <https://www.stemcell.co.jp/corporate/>

Group Companies: STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milcare Co., Ltd.

[For media inquiries regarding this announcement]

StemCell Institute Inc.

Corporate Planning Division

TEL: 03-6811-3235 / MAIL: ir@stemcell.co.jp

iPS Portal Co., Ltd.

Corporate Strategy Department

TEL: 075-707-1057 / MAIL: RSD@ipsportal.com